GlassScriptPhysician profile
Yuchen Liu
NPI 1962994004
$1,266.42
in general payments reported to CMS, 2019-2025
12 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $688 · 2023: $267 · 2024: $64.69 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $200.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $147.01 | 2023 | |
| Abbvie INC. | $125.00 | 2022 | |
| Puma Biotechnology, INC. | $124.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $119.70 | 2022 | |
| Gilead Sciences, INC. | $119.60 | 2023 | Trodelvy |
| Genzyme Corporation | $118.34 | 2022 | |
| Daiichi Sankyo INC. | $98.18 | 2025 | Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $91.43 | 2025 | |
| Celgene Corporation | $64.69 | 2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $29.07 | 2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $28.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuchen Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.